The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 28, 2023

Filed:

Jul. 05, 2018
Applicant:

Chugai Seiyaku Kabushiki Kaisha, Tokyo, JP;

Inventors:

Tomoyuki Igawa, Shizuoka, JP;

Atsuhiko Maeda, Shizuoka, JP;

Shigero Tamba, Shizuoka, JP;

Takehisa Kitazawa, Shizuoka, JP;

Takeshi Baba, Shizuoka, JP;

Yoshinao Ruike, Shizuoka, JP;

Junichi Nezu, Shizuoka, JP;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/24 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/18 (2006.01); C07K 16/22 (2006.01);
U.S. Cl.
CPC ...
C07K 16/24 (2013.01); C07K 16/00 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/248 (2013.01); C07K 16/2866 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/64 (2013.01); C07K 2317/70 (2013.01); C07K 2317/71 (2013.01); C07K 2317/72 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.


Find Patent Forward Citations

Loading…